menu search

GRCL / Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F at 2023 ASCO Annual Meeting

Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F at 2023 ASCO Annual Meeting
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China , April 26, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will present updated clinical data on GC012F, the Company's FasTCAR-enabled autologous CAR-T cell therapy dual-targeting B-cell maturation antigen (BCMA) and CD19, from ongoing investigator-initiated trials (IIT) in relapsed-refractory multiple myeloma (RRMM) and B-cell non-Hodgkin's lymphoma (B-NHL) at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 2-6, 2023, in Chicago and online. Read More
Posted: Apr 26 2023, 10:15
Author Name: PRNewsWire
Views: 082547

GRCL News  

Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences

By GlobeNewsWire
November 1, 2023

Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences

SAN DIEGO and SUZHOU, China and SHANGHAI, China, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDA more_horizontal

Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences

By GlobeNewsWire
September 14, 2023

Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences

SAN DIEGO and SUZHOU, China and SHANGHAI, China, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a gl more_horizontal

Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences

By GlobeNewsWire
August 24, 2023

Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences

SAN DIEGO and SUZHOU, China and SHANGHAI, China, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a glob more_horizontal

Gracell Biotechnologies Inc. (GRCL) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 14, 2023

Gracell Biotechnologies Inc. (GRCL) Q2 2023 Earnings Call Transcript

Gracell Biotechnologies Inc. (NASDAQ:GRCL ) Q2 2023 Earnings Conference Call August 14, 2023 8:00 AM ET Company Participants William Cao - Chairman, C more_horizontal

Why Shares of Gracell Biotechnologies Are Rising Monday

By The Motley Fool
August 7, 2023

Why Shares of Gracell Biotechnologies Are Rising Monday

Gracell Biotechnologies is a clinical-stage biotech company based in China. The company's lead therapy is in four different trials to treat various di more_horizontal

Gracell Biotechnologies to Report Second Quarter 2023 Financials on Monday, August 14, 2023

By GlobeNewsWire
July 31, 2023

Gracell Biotechnologies to Report Second Quarter 2023 Financials on Monday, August 14, 2023

SAN DIEGO and SUZHOU, China and SHANGHAI, China, July 31, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a glob more_horizontal

Gracell Biotechnologies (GRCL) Surges 62% in a Week: Here's Why

By Zacks Investment Research
June 14, 2023

Gracell Biotechnologies (GRCL) Surges 62% in a Week: Here's Why

Shares of Gracell (GRCL) increase after it reported positive data from two clinical studies, which evaluated its experimental CAR T cell therapy drug more_horizontal

Why Shares of Gracell Biotechnologies Jumped Tuesday

By The Motley Fool
June 13, 2023

Why Shares of Gracell Biotechnologies Jumped Tuesday

Two analysts upgraded their ratings for Gracell Biotechnologies' stock. Over the weekend, Gracell announced positive follow-up trial data regarding it more_horizontal


Search within

Pages Search Results: